hr

Hot Keywords
non-alcoholic fatty liver disease epidemiology microenvironment nonalcoholic steatohepatitis transplantation cholangiocarcinoma direct-acting antiviral immunotherapy hepatitis B hepatitis C liver resection imaging cancer stem cell diagnosis gene cirrhosis biomarker recurrence

Top
Topic: Systemic Treatment for Hepatocellular Carcinoma

A special issue of Hepatoma Research

ISSN 2454-2520 (Online), ISSN 2394-5079 (Print)

Submission deadline: 1 Jul 2021

Guest Editor(s)

  • Flair José Carrilho, MD, PhD
    EASL International Recognition Award Recipient 2019;
    Full Professor of Division of Clinical Gastroenterology and Hepatology, Hospital das Clínicas HCFMUSP, Department of Gastroenterology, University of São Paulo School of Medicine, Sao Paulo, Brazil.

    Website | E-mail

Special Issue Introduction

The systemic treatment of advanced hepatocellular carcinoma has rapidly evolved in the last years. Until the demonstration of the survival benefit of sorafenib in 2007, no effective treatments were available. The positive results with sorafenib represented a major breakthrough and triggered interest in the evaluation of new agents. After multiple failures, recent agents have proven benefit, significantly extending the survival of advanced hepatocellular carcinoma. This hopeful scenario has been crowned by the recently published results of the IMBRAVE-150 trial. This trial proved superiority of atezolizumab plus bevacizumab over sorafenib.

Currently, several ongoing trials are evaluating the activity of dual immunotherapy combinations or combinations of tyrosine kinase inhibitors plus immunotherapy. Some of these results are planned to be announced in the following years.
Within this context, it is possible to state that advanced HCC will move from a rapidly lethal malignancy to a chronic condition. This will require critical insight and deep knowledge of the available data.

We invite you to contribute to the upcoming special issue about "Systemic Treatment for Hepatocellular Carcinoma" and hope you will be able to join us in this journey.

The following topics are what we would like to to discuss in this special issue:
1. Combination immunotherapy + TKI
2. Combination dual immunotherapy
3. Potential biomarkers of response to systemic treatment
4. Mechanisms of resistance in HCC
5. Sequencing strategies
6. Tyrosine kinase inhibitors
7. Role of immunotherapy
8. Combination of systemic treatment and local modalities
9. (Neo) adjuvant systemic treatment
10. Radiological response assessment in patients under systemic treatment

Participants

1. Leonardo G. da Fonseca  Medical Oncology, São Paulo Clínicas Liver Cancer Group, Hospital das Clínicas Complex, Instituto do Cancer do Estado de São Paulo, University of São Paulo School of Medicine, São Paulo, Brazil.
2. Nikolaos T. Pyrsopoulos  Division of Gastroenterology & Hepatology, Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA.
3. Philippe Merle  Department of Hepatology, Hospices Civils de Lyon, Croix-Rousse University Hospital, Claude Bernard Lyon 1 University, Lyon, France.
4. Elias Kouroumalis  Liver Research Laboratory, University of Crete Medical School, Heraklion, Greece.
5. Alessandro Rizzo  Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
6. Riccardo Carloni  Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
7. Chimaobi Anugwom  Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN, USA..
The list is arranged in no particular order and being updated.

Submission Deadline

1 Jul 2021

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://hrjournal.net/pages/view/author_instructions
For Online Submission, please login at https://oaemesas.com/HR/?IssueId=555
Submission Deadline: 1 Jul 2021
Contacts: Victoria Lee, Assistant Editor, editor_Victoria@hrjournal.net

Published Articles

© 2016-2021 OAE Publishing Inc., except certain content provided by third parties